Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00:01 2023-01-31 pm EST
17.01 USD   -0.18%
07:07aDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
BU
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outperform Rating
MT
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about DECIPHERA PHARMACEUTICALS, INC.
07:07aDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Resul..
BU
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outp..
MT
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clin..
BU
01/24Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full..
BU
01/24Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase ..
CI
01/23Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
AQ
01/20Deciphera Pharmaceuticals Prices $125 Million Common Stock Offering
MT
01/19Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BU
01/19Deciphera Pharmaceuticals Plans $125 Million Common Stock Offering -- Shares Down Pre-B..
MT
01/18Deciphera Pharmaceuticals Plans $125 Million Common Stock Offering; Shares Fall After H..
MT
01/18Deciphera Pharmaceuticals : Other Information - Form 8-K
PU
01/18Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
BU
01/09Transcript : Deciphera Pharmaceuticals, Inc. Presents at 41st Annual J.P. Mor..
CI
01/06JonesTrading Upgrades Deciphera Pharmaceuticals to Hold From Sell
MT
01/04SVB Securities Raises Price Target on Deciphera Pharmaceuticals to $28 From $25, Keeps ..
MT
More most relevant news
All news about DECIPHERA PHARMACEUTICALS, INC.
07:07aDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Resul..
BU
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outp..
MT
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clin..
BU
01/24Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full..
BU
01/24Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase ..
CI
01/23Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
AQ
01/20Deciphera Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Financial St..
AQ
01/20Deciphera Pharmaceuticals Prices $125 Million Common Stock Offering
MT
01/19Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BU
01/19Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
MT
More news
News in other languages on DECIPHERA PHARMACEUTICALS, INC.
01/24Deciphera Pharmaceuticals, Inc. présente les résultats de l'analyse de l'ADNc de l'étud..
01/20Deciphera Pharmaceuticals lance une offre d'actions ordinaires pour un montant de 125 m..
01/19Mise à jour sectorielle : Les actions du secteur de la santé son..
01/19Deciphera Pharmaceuticals propose une offre d'actions ordinaires de 125 millions de dol..
01/18Deciphera Pharmaceuticals propose une offre d'actions ordinaires de 125 millions de dol..
01/03Deciphera Pharmaceuticals enregistre des revenus plus élevés au quatrième trimestre
01/03Deciphera Pharmaceuticals, Inc. fournit des prévisions préliminaires non vérifiées de r..
01/03Deciphera Pharmaceuticals, Inc. Pharmaceuticals annonce les résultats de l'analyse de l..
2022Deciphera Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et le..
2022Deciphera Pharmaceuticals, Inc. Présente des données actualisées de phase 1/2 pour le V..
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outp..
MT
01/06JonesTrading Upgrades Deciphera Pharmaceuticals to Hold From Sell
MT
01/04SVB Securities Raises Price Target on Deciphera Pharmaceuticals to $28 From $25, Keeps ..
MT
01/04Barclays Adjusts Deciphera Pharmaceuticals Price Target to $9 From $8, Maintains Underw..
MT
01/04Guggenheim Upgrades Deciphera Pharmaceuticals to Buy From Neutral, Price Target is $22
MT
More recommendations
Press releases
07:07aDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Resul..
BU
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clin..
BU
01/24Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full..
BU
01/23Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
AQ
01/20Deciphera Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Financial St..
AQ
More press releases
Upcoming event on DECIPHERA PHARMACEUTICALS, INC.